Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFH312 in Peripheral Artery Disease and Intermittent Claudication
NCT05618691Phase 2Withdrawn
- Sponsor
- GenFleet Therapeutics
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GFH312 in peripheral artery disease (PAD), sponsored by GenFleet Therapeutics. Planned start Dec 2022; status: withdrawn.
02
Drugs
GFH312
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT05618691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05618691.